LSV Asset Management Has $367,000 Stock Position in ACADIA Pharmaceuticals Inc. $ACAD

LSV Asset Management lowered its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 91.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 17,200 shares of the biopharmaceutical company’s stock after selling 192,800 shares during the period. LSV Asset Management’s holdings in ACADIA Pharmaceuticals were worth $367,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ACAD. Thrivent Financial for Lutherans increased its holdings in shares of ACADIA Pharmaceuticals by 0.7% in the second quarter. Thrivent Financial for Lutherans now owns 91,067 shares of the biopharmaceutical company’s stock worth $1,964,000 after acquiring an additional 626 shares in the last quarter. GAMMA Investing LLC increased its stake in ACADIA Pharmaceuticals by 25.8% during the 3rd quarter. GAMMA Investing LLC now owns 3,361 shares of the biopharmaceutical company’s stock worth $72,000 after purchasing an additional 690 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in ACADIA Pharmaceuticals by 113.0% during the 3rd quarter. Geneos Wealth Management Inc. now owns 1,425 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 756 shares during the period. Yousif Capital Management LLC lifted its stake in ACADIA Pharmaceuticals by 1.7% in the second quarter. Yousif Capital Management LLC now owns 46,773 shares of the biopharmaceutical company’s stock valued at $1,009,000 after buying an additional 790 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its holdings in shares of ACADIA Pharmaceuticals by 107.0% in the third quarter. Smartleaf Asset Management LLC now owns 1,712 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 885 shares during the period. 96.71% of the stock is currently owned by institutional investors.

Insider Transactions at ACADIA Pharmaceuticals

In other news, EVP Jennifer J. Rhodes sold 6,950 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $23.38, for a total transaction of $162,491.00. Following the completion of the transaction, the executive vice president directly owned 7,609 shares in the company, valued at approximately $177,898.42. The trade was a 47.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 28.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on ACAD shares. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ACADIA Pharmaceuticals in a research report on Monday, December 29th. Royal Bank Of Canada cut their price target on ACADIA Pharmaceuticals from $35.00 to $31.00 and set an “outperform” rating on the stock in a report on Tuesday, February 3rd. UBS Group increased their price objective on ACADIA Pharmaceuticals from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Wall Street Zen lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Finally, Oppenheimer reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.95.

ACADIA Pharmaceuticals Price Performance

ACADIA Pharmaceuticals stock opened at $22.95 on Wednesday. The company’s 50-day moving average is $25.93 and its 200-day moving average is $24.44. The firm has a market capitalization of $3.88 billion, a PE ratio of 14.81, a P/E/G ratio of 7.73 and a beta of 0.66. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $13.40 and a fifty-two week high of $28.35.

ACADIA Pharmaceuticals Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.